This is at that the higher end maybe of what you had expected based on your comments, but I think the fit with the portfolio we have and the attractiveness of the margins as I commented on in my comments was a great opportunity for us to diversify and expand our surgical platform, but our capital deployment strategy is certainly unchanged.